Načítá se...
KRAS G12C inhibition and innate immune targeting
INTRODUCTION: KRAS mutations drive tumorigenesis by altering cell signaling and the tumor immune microenvironment. Recent studies have shown promise for KRAS-G12C covalent inhibitors, which are advancing rapidly through clinical trials. The sequencing and combination of these agents with other thera...
Uloženo v:
| Vydáno v: | Expert Opin Ther Targets |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8122058/ https://ncbi.nlm.nih.gov/pubmed/33703985 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14728222.2021.1902991 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|